HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
Antiretroviral Prophylaxis: A Defining Moment in HIV Control
Lancet 378:e23-25, Karim, S.S. and Karim, Q.A., 2011
Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Ocular Manifestations of AIDS
JAMA 275:142-144, 1491996., Whitcup,S.M., 1996
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders
JAMA Neurol 77:927-928, Bloem, B.R.,et al, 2020
Dilemmas in the Diagnosis of Acute Community-Acquired Bacterial Meningitis
Lancet 380:1684-1692,1623, Brouwer, M.,et al, 2012
Advances in Treatment of Bacterial Meningitis
Lancet 380:1693-1702,1623, Van de Beek, D.,et al, 2012
Spinal Muscular Atrophy A Timely Review
Arch Neurol 68:979-984, Kolb, S.J.,et al, 2011
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Safety and Tolerability of Gene Therapy With an Adeno-Associated Virus (AAV) Borne GAD gene for Parkinsons Disease: An Open Label, Phase I Trial
Lancet 369:2097-2105,2056, Kaplitt,M.G.,et al, 2007
Recent Developments in Bell's Palsy
BMJ 329:553-557, Holland,N.J. & Weiner,G.M., 2004
Neurovirological Methods and Their Applications
JNNP 74:1016-1022, Kennedy,P.G.E., 2003
Management of Epilepsy in Adolescents and Adults
Lancet 356:323-329, Brodie,M.J. & French,J.A., 2000
The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform Encephalopathies
NEJM 335:924-930, 9631996., Hsich,G.,et al, 1996
Trinucleotide Repeat Expansion in Neurological Disease
Ann Neurol 36:814-822, LaSpada,A.R.,et al, 1994
Recommendations for the Establishment of Stroke Systems of Care
Stroke 50:e1-e24, Adeoye, O.,et al, 2019
Stroke
Lancet 389:641-654, Hankey, G.J., 2017
Endovascular Thrombectomy of Ischemic Stroke
JAMA 316:1265-1266, Warach, S. & Johnston, C., 2016
Implementing a Mobile Stroke Unit Program in the United States
JAMA Neurol 72:229-234, Rajan, S.,et al, 2015
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma
JAMA 314:2535-2543,2511, Stupp, R.,et al, 2015
MATILDE Chemotherapy Regimen for Primary CNS Lymphoma
Neurol 82:1370-1373, Ferreri, A.J.M.,et al, 2014
Therapeutic Devices for Epilepsy
Ann Neurol 71:157-168, Fisher,R.S., 2012
Solitaire Flow Restoration Device Versus the Merci Retriever in Patients with Acute Ischaemic Stroke (SWIFT): a Randomised, Parallel-Group, Non-Inferiority Trial
Lancet 380:1241-1249,1208, Saver, J.L.,et al, 2012
Effect of Vaccines on Bacterial Meningitis Worldwide
Lancet 380:1703-1711,1623, McIntyre, P.,et al, 2012
Contemporary management and recent advances in paediatric hydrocephalus
BMJ 343:d4191, Kandasamy, J.,et al, 2011
Current Concepts and Management of Glioblastoma
Ann Neurol 70:9-21, Preusser, M.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Diagnosis and New Treatments in Muscular Dystrophies
JNNP 80:706-714, Manzur,A.Y. &Muntoni,F., 2009
Diagnosis and Management of Motor Neurone Disease
BMJ 336:658-662, McDermott,C.J. &Shaw,P.J., 2008
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Glioma Therapy in Adults
The Neurologist 12:279-292, Norden,A.D. &Wen,P.Y., 2006
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
NEJM 352:987-996, 1036, Stupp,R., et al, 2005
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
NEJM 352:997-1003, 1036, Hegi,M.E., et al, 2005
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
NEJM 352:10 978-986, 1036, Rutkowski,S., et al, 2005
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
JAMA 293:557-564,615, Chang,S.M.,et al, 2005
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Expanding the Range of Therapies for Acute Ischemic Stroke: The Early Experience of the Regional Stroke Center at Hartford Hospital
Connecticut Medicine 68:419-429, Silvernman,I.E.,et al, 2004